1-6 of 6
Gerald Batist
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes

Mathilde Couëtoux du Tertre, Maud Marques, Lise Tremblay, Nicole Bouchard, Razvan Diaconescu, Normand Blais, Christian Couture, Vincent Pelsser, Hangjun Wang, Valerie Higenell, Luisa Izzi, Karen Gambaro, Cyrla Hoffert, Archana Srivastava, Alan Spatz, Caroline Rousseau, Suzan McNamara, Victor Cohen, Gerald Batist, Jason Agulnik
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (9): 1628–1636.
https://doi.org/10.1158/1535-7163.MCT-19-0105
Published: 03 September 2019
View article titled, Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Open the PDF for Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes in another window
Includes: Supplementary data
Journal Articles

Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy

Martin Loignon, Weimin Miao, Lianggao Hu, Andrew Bier, Tarek A. Bismar, P. James Scrivens, Koren Mann, Mark Basik, Amélie Bouchard, Pierre O. Fiset, Zachary Batist, Gerald Batist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (8): 2432–2440.
https://doi.org/10.1158/1535-7163.MCT-08-1186
Published: 14 August 2009
View article titled, Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy
Open the PDF for Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy in another window
Journal Articles

Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target

Andrew Bier, Irene Oviedo-Landaverde, Jing Zhao, Yael Mamane, Mustapha Kandouz, Gerald Batist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (4): 786–793.
https://doi.org/10.1158/1535-7163.MCT-08-0930
Published: 16 April 2009
View article titled, <em>Connexin43</em> pseudogene in breast cancer cells offers a novel therapeutic target
Open the PDF for <em>Connexin43</em> pseudogene in breast cancer cells offers a novel therapeutic target in another window
Journal Articles

A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease

Gerald Batist, Anthony Tolcher, John Sarantopoulos, Kamalesh Sankhala, Jeannie Fontanilla, Biao Lu, Gavin Choy, Steven Deitcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A150.
Published: 01 November 2007
View article titled, A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease
Journal Articles

Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent

Pierre Falardeau, Sharyn D. Baker, Petr Kavan, Benoit Samson, Robert Belanger, Maxime Ranger, Michael D. Harvey, Gerald Batist
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B119.
Published: 01 November 2007
View article titled, Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
Journal Articles

Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues

P. James Scrivens, Moulay A. Alaoui-Jamali, Giuseppe Giannini, Taiqi Wang, Martin Loignon, Gerald Batist, Victor A. Sandor
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (10): 1053–1059.
Published: 24 October 2003
View article titled, Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues
Open the PDF for Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues in another window